181 related articles for article (PubMed ID: 37981266)
1. Impact of Bempedoic acid on LDL-C reduction and cardiovascular outcomes: A comprehensive meta-analysis of randomized controlled trials.
Del Carpio-Tenorio C; Llerena-Velastegui J; Villacis-Lopez C; Placencia-Silva M; Santander-Fuentes C; Benitez-Acosta K; Sanahuja-Montiel C; Dominguez-Gavilanes D; Carrasco-Perez P; Calderon-Lopez C
Curr Probl Cardiol; 2024 Feb; 49(2):102191. PubMed ID: 37981266
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
[TBL] [Abstract][Full Text] [Related]
3. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and outcomes of Bempedoic acid versus placebo in patients with statin-intolerance: A pilot systematic review and meta-analysis of randomized controlled trials.
Goyal A; Changez MIK; Tariq MD; Mushtaq F; Shamim U; Sohail AH; Mahalwar G
Curr Probl Cardiol; 2024 Feb; 49(2):102236. PubMed ID: 38043880
[TBL] [Abstract][Full Text] [Related]
5. Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant.
Doggrell SA
Expert Opin Pharmacother; 2023; 24(15):1673-1677. PubMed ID: 37496276
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bempedoic acid lipid-lowering therapy: a systematic review and meta-analysis of randomized controlled trials.
Venkatraman S; Das S; Eerike M; Cherian JJ; Bagepally BS
Eur J Clin Pharmacol; 2023 Nov; 79(11):1453-1463. PubMed ID: 37672112
[TBL] [Abstract][Full Text] [Related]
7. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.
Ray KK; Nicholls SJ; Li N; Louie MJ; Brennan D; Lincoff AM; Nissen SE;
Lancet Diabetes Endocrinol; 2024 Jan; 12(1):19-28. PubMed ID: 38061370
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.
Laufs U; Ballantyne CM; Banach M; Bays H; Catapano AL; Duell PB; Goldberg AC; Gotto AM; Leiter LA; Ray KK; Bloedon LT; MacDougall D; Zhang Y; Mancini GBJ
J Clin Lipidol; 2022; 16(3):286-297. PubMed ID: 35346603
[TBL] [Abstract][Full Text] [Related]
10. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP).
Banach M; Penson PE; Farnier M; Fras Z; Latkovskis G; Laufs U; Paneni F; Parini P; Pirro M; Reiner Ž; Vrablik M; Escobar C
Prog Cardiovasc Dis; 2023; 79():2-11. PubMed ID: 36889490
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials.
De Filippo O; D'Ascenzo F; Iannaccone M; Bertaina M; Leone A; Borzillo I; Ravetti E; Solano A; Pagliassotto I; Nebiolo M; Bruno F; Giacobbe F; Muscoli S; Monticone S; Brizzi MF; Biondi Zoccai G; De Ferrari GM
Cardiovasc Diabetol; 2023 Nov; 22(1):324. PubMed ID: 38017541
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis.
Wang X; Zhang Y; Tan H; Wang P; Zha X; Chong W; Zhou L; Fang F
Cardiovasc Diabetol; 2020 Aug; 19(1):128. PubMed ID: 32787939
[TBL] [Abstract][Full Text] [Related]
13. Bempedoic Acid can Reduce Cardiovascular Events in Combination with Statins or As Monotherapy: A Systematic Review and Meta-analysis.
Zhang J; Guan X; Zhang B; Wang J; Jin X; Zhao Y; Li B
Am J Cardiovasc Drugs; 2023 Nov; 23(6):695-708. PubMed ID: 37672202
[TBL] [Abstract][Full Text] [Related]
14. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
Susekov AV; Korol LA; Watts GF
Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
[TBL] [Abstract][Full Text] [Related]
15. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE; Lincoff AM; Brennan D; Ray KK; Mason D; Kastelein JJP; Thompson PD; Libby P; Cho L; Plutzky J; Bays HE; Moriarty PM; Menon V; Grobbee DE; Louie MJ; Chen CF; Li N; Bloedon L; Robinson P; Horner M; Sasiela WJ; McCluskey J; Davey D; Fajardo-Campos P; Petrovic P; Fedacko J; Zmuda W; Lukyanov Y; Nicholls SJ;
N Engl J Med; 2023 Apr; 388(15):1353-1364. PubMed ID: 36876740
[TBL] [Abstract][Full Text] [Related]
16. Clinical Efficacy and Safety of Bempedoic Acid in High Cardiovascular Risk Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Uddin N; Syed AA; Ismail SM; Ashraf MT; Khan MK; Sohail A
Curr Probl Cardiol; 2023 Dec; 48(12):102003. PubMed ID: 37516330
[TBL] [Abstract][Full Text] [Related]
17. Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol.
Toth PP; Bray S; Villa G; Palagashvili T; Sattar N; Stroes ESG; Worth GM
J Am Heart Assoc; 2022 Sep; 11(18):e025551. PubMed ID: 36073669
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.
Nicholls S; Lincoff AM; Bays HE; Cho L; Grobbee DE; Kastelein JJ; Libby P; Moriarty PM; Plutzky J; Ray KK; Thompson PD; Sasiela W; Mason D; McCluskey J; Davey D; Wolski K; Nissen SE
Am Heart J; 2021 May; 235():104-112. PubMed ID: 33470195
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.
Gunta SP; O'Keefe JH; O'Keefe EL; Lavie CJ
Prog Cardiovasc Dis; 2023; 79():12-18. PubMed ID: 36871887
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials.
Zhao X; Ma X; Luo X; Shi Z; Deng Z; Jin Y; Xiao Z; Tan L; Liu P; Jiang S; Shu Y; Tang B; Qiu C
BMC Pharmacol Toxicol; 2020 Dec; 21(1):86. PubMed ID: 33276805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
